COVID-19 Vaccine in Pregnant and Lactating Women: A Review of Existing Evidence and Practice Guidelines
- PMID: 34449637
- PMCID: PMC8395843
- DOI: 10.3390/idr13030064
COVID-19 Vaccine in Pregnant and Lactating Women: A Review of Existing Evidence and Practice Guidelines
Abstract
Coronavirus 2019 (COVID-19) has created a global pandemic that is devastating human lives, public healthcare systems, and global economies. Multiple effective and safe COVID-19 vaccines have been developed at an unprecedented speed due to the efforts of the scientific community, and collaboration between the federal government and pharmaceutical companies. However, the continued exclusion of pregnant and lactating women from the COVID anti-viral and vaccine trials has created the paradox of a lack of empirical evidence in a high-risk population. Based on the experience of similar prior vaccines, animal developmental and reproductive toxicology studies, and preliminary findings from human studies, various healthcare professional advisory committees (Advisory Committee on Immunization Practices, American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine, and Academy of Breastfeeding Medicine) have issued guidance supporting COVID-19 vaccination in pregnant and lactating women. In this article, we summarize the available data on the efficacy and safety profile of COVID-19 vaccination in pregnant and lactating women, review the challenges of vaccine hesitancy, and include recommendations for healthcare providers.
Keywords: COVID-19; COVID-19 vaccines; Coronavirus 2019; breast feeding; fertility; lactation; pregnancy; vaccine.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- WHO WHO Coronavirus (COVID-19) Dashboard. [(accessed on 5 June 2021)]; Available online: https://covid19.who.int.
-
- Bank W. COVID-19 to Add as Many as 150 Million Extreme Poor by 2021 World Bank. [(accessed on 5 June 2021)]; Available online: https://www.world bank.org/en/news/press-release/2020/10/07/covid-19-to-....
-
- Pfizer Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study. [(accessed on 5 June 2021)]; Available online: https://investors.pfizer.com/investor-news/press-release-details/2020/Pf....
-
- Moderna Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization. [(accessed on 5 June 2021)]; Available online: https://investors.modernatx.com/news-releases/news-release-details/moder....
-
- Zimmer C.C.J., Wee S. Coronavirus Vaccine Tracker. [(accessed on 5 June 2021)]; Available online: https://www.nytimes.com/interactive/2020/science/coron avirus-vaccine-tr....
Publication types
LinkOut - more resources
Full Text Sources
